http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 06:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Apollomics+Inc.++++++++++++++++++++++/26594877.html si-local-file:///var/storage/secattach/20260603/26594877.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Apollomics+Inc.++++++++++++++++++++++/26594877.html Wed, 03 Jun 2026 06:05:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Apollomics+Inc.++++++++++++++++++++++/26594877.html si-local-file:///var/storage/secattach/20260603/26594877.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Apollomics+Inc.++++++++++++++++++++++/26594877.html Wed, 03 Jun 2026 06:05:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+May+17++Filed+by%3A+Huang+Ya-Chi/26519716.html si-local-file:///var/storage/secattach/20260519/26519716.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+May+17++Filed+by%3A+Huang+Ya-Chi/26519716.html Tue, 19 May 2026 12:06:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+May+17++Filed+by%3A+Huang+Ya-Chi/26519716.html si-local-file:///var/storage/secattach/20260519/26519716.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+May+17++Filed+by%3A+Huang+Ya-Chi/26519716.html Tue, 19 May 2026 12:06:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++F-3A++++++Apollomics+Inc.++++++++++++++++++++++/26506187.html si-local-file:///var/storage/secattach/20260515/26506187.html http://www.streetinsider.com/SEC+Filings/Form++F-3A++++++Apollomics+Inc.++++++++++++++++++++++/26506187.html Fri, 15 May 2026 16:28:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++F-3A++++++Apollomics+Inc.++++++++++++++++++++++/26506187.html si-local-file:///var/storage/secattach/20260515/26506187.html http://www.streetinsider.com/SEC+Filings/Form++F-3A++++++Apollomics+Inc.++++++++++++++++++++++/26506187.html Fri, 15 May 2026 16:28:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Apollomics+Inc.+++++++++++For%3A+Apr+27/26370290.html si-local-file:///var/storage/secattach/20260427/26370290.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Apollomics+Inc.+++++++++++For%3A+Apr+27/26370290.html Mon, 27 Apr 2026 08:20:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Apollomics+Inc.+++++++++++For%3A+Apr+27/26370290.html si-local-file:///var/storage/secattach/20260427/26370290.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Apollomics+Inc.+++++++++++For%3A+Apr+27/26370290.html Mon, 27 Apr 2026 08:20:00 -0400 APLM O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Press+Releases/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html <ul><li style="text-align:left;"><em>Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.</em></li><li style="text-align:left;"><em>To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.</em></li><li style="text-align:left;"><em>Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC.</em><br/></li></ul> <p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZOEVpQFhu4Ndls-Pgtsf4RPjAC2QobUhOOpaBW2nzN0fKSVjfJYiK14SgbVNnVyYnjls-r_c=" rel="nofollow" target="_blank">Apollomics Inc.</a> (Nasdaq: APLM), a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment http://www.streetinsider.com/Globe+Newswire/Apollomics+Reports+Full+Year+2025+Financial+Results+and+Provides+Clinical+Updates+and+Business+Progress/26370001.html Mon, 27 Apr 2026 08:00:00 -0400 A.06822034 APLM APLMW O.20026344 O.53171576 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Apollomics+Inc.+++++++++++For%3A+Dec+31/26366551.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260424/AU2ZB22DZZ2RK2ZZ27ZR2WYOGQMBZZ22Z886">http://archive.fast-edgar.com/20260424/AU2ZB22DZZ2RK2ZZ27ZR2WYOGQMBZZ22Z886</a></p> <p> Filed on: April 24, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Apollomics+Inc.+++++++++++For%3A+Dec+31/26366551.html Fri, 24 Apr 2026 16:24:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Apollomics+Inc.+++++++++++For%3A+Dec+31/26366551.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260424/AU2ZB22DZZ2RK2ZZ27ZR2WYOGQMBZZ22Z886">http://archive.fast-edgar.com/20260424/AU2ZB22DZZ2RK2ZZ27ZR2WYOGQMBZZ22Z886</a></p> <p> Filed on: April 24, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++Apollomics+Inc.+++++++++++For%3A+Dec+31/26366551.html Fri, 24 Apr 2026 16:24:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Apollomics+Inc.+++++++++++For%3A+Mar+18++Filed+by%3A+CHEN+HONG-JUNG/26331998.html si-local-file:///var/storage/secattach/20260417/26331998.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Apollomics+Inc.+++++++++++For%3A+Mar+18++Filed+by%3A+CHEN+HONG-JUNG/26331998.html Fri, 17 Apr 2026 19:13:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Apollomics+Inc.+++++++++++For%3A+Mar+18++Filed+by%3A+CHEN+HONG-JUNG/26331998.html si-local-file:///var/storage/secattach/20260417/26331998.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Apollomics+Inc.+++++++++++For%3A+Mar+18++Filed+by%3A+CHEN+HONG-JUNG/26331998.html Fri, 17 Apr 2026 19:13:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+Mar+31++Filed+by%3A+LIN+PETER+KUAN-HOW/26331994.html si-local-file:///var/storage/secattach/20260417/26331994.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+Mar+31++Filed+by%3A+LIN+PETER+KUAN-HOW/26331994.html Fri, 17 Apr 2026 19:06:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+Mar+31++Filed+by%3A+LIN+PETER+KUAN-HOW/26331994.html si-local-file:///var/storage/secattach/20260417/26331994.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Apollomics+Inc.+++++++++++For%3A+Mar+31++Filed+by%3A+LIN+PETER+KUAN-HOW/26331994.html Fri, 17 Apr 2026 19:06:00 -0400 APLM O.53171576 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Apollomics+Inc.+++++++++++For%3A+Mar+18++Filed+by%3A+Jan+Chen-Huan/26313315.html si-local-file:///var/storage/secattach/20260414/26313315.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Apollomics+Inc.+++++++++++For%3A+Mar+18++Filed+by%3A+Jan+Chen-Huan/26313315.html Tue, 14 Apr 2026 20:03:00 -0400 APLM O.53171576